Oncology & Cancer

FDA approves 'game changer' immunotherapy drug for bladder cancer

A new immunotherapy drug, atezolizumab, has been approved for patients with metastatic urothelial carcinoma, a type of bladder cancer. The drug represents the first new treatment for this form of the disease in more than ...


Atezolizumab prolongs survival in NSCLC with PD-L1 expression

(HealthDay)—For patients with non-small cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression, treatment with atezolizumab results in longer overall survival than chemotherapy, according to a study ...

Oncology & Cancer

Atezolizumab + bevacizumab shows benefit in met renal CA

(HealthDay)—For patients with metastatic renal cell carcinoma (mRCC), atezolizumab plus bevacizumab is associated with a progression-free survival benefit versus sunitinib, according to a study presented at the American ...

page 1 from 2